BACKGROUND: Interleukin (IL)-15 is one of the cytokines produced by neutrophils and monocytes/macrophages, and its expression is found immunohistochemically in inflammatory cells adjacent to vulnerable atherosclerotic plaques. However, the influence of systemic IL-15 on cardiovascular disease is still unclear. Therefore, we designed clinical investigations to clarify the relationship between cardiovascular complications and serum IL-15 levels. METHODS AND RESULTS: Three hundred ninety-nine patients with essential hypertension were analyzed. We divided the study subjects into the following three groups according to the modified World Health Organization-International Society of Hypertension classification of 1999: patients with no organ damage (n = 213), patients with mild organ damage (n = 128), and patients with severe organ damage (n = 58). We measured serum IL-15, highly sensitive C reactive protein, IL-6, soluble intercellular adhesion molecule, and soluble vascular cell adhesion molecule levels. Serum IL-15 concentration in patients with severe organ damage was significantly higher than that in those with no organ damage (P < .01) and those with mild organ damage (P < .01). Serum IL-15 concentration in patients with coronary artery disease or peripheral artery disease was significantly higher than that in those without coronary artery disease or peripheral artery disease. Moreover, serum IL-15 concentration in patients with lacunar infarction was significantly higher than that in those without lacunar infarction (P < .005). By multiple linear logistic regression analysis, serum IL-15 concentration was independently correlated with cardiovascular disease. CONCLUSIONS: These data suggest that a systemic inflammatory response involving IL-15 might be involved in the occurrence of cardiovascular disease in patients with essential hypertension.
BACKGROUND:Interleukin (IL)-15 is one of the cytokines produced by neutrophils and monocytes/macrophages, and its expression is found immunohistochemically in inflammatory cells adjacent to vulnerable atherosclerotic plaques. However, the influence of systemic IL-15 on cardiovascular disease is still unclear. Therefore, we designed clinical investigations to clarify the relationship between cardiovascular complications and serum IL-15 levels. METHODS AND RESULTS: Three hundred ninety-nine patients with essential hypertension were analyzed. We divided the study subjects into the following three groups according to the modified World Health Organization-International Society of Hypertension classification of 1999: patients with no organ damage (n = 213), patients with mild organ damage (n = 128), and patients with severe organ damage (n = 58). We measured serum IL-15, highly sensitive C reactive protein, IL-6, soluble intercellular adhesion molecule, and soluble vascular cell adhesion molecule levels. Serum IL-15 concentration in patients with severe organ damage was significantly higher than that in those with no organ damage (P < .01) and those with mild organ damage (P < .01). Serum IL-15 concentration in patients with coronary artery disease or peripheral artery disease was significantly higher than that in those without coronary artery disease or peripheral artery disease. Moreover, serum IL-15 concentration in patients with lacunar infarction was significantly higher than that in those without lacunar infarction (P < .005). By multiple linear logistic regression analysis, serum IL-15 concentration was independently correlated with cardiovascular disease. CONCLUSIONS: These data suggest that a systemic inflammatory response involving IL-15 might be involved in the occurrence of cardiovascular disease in patients with essential hypertension.
Authors: Donna K Arnett; Richard B Devereux; Dabeeru C Rao; Na Li; Weihong Tang; Rachel Kraemer; Steven A Claas; Joanlise M Leon; Ulrich Broeckel Journal: J Hypertens Date: 2009-08 Impact factor: 4.844
Authors: Elena Dozio; Alexis Elias Malavazos; Elena Vianello; Silvia Briganti; Giada Dogliotti; Francesco Bandera; Francesca Giacomazzi; Serenella Castelvecchio; Lorenzo Menicanti; Alexander Sigrüener; Gerd Schmitz; Massimiliano Marco Corsi Romanelli Journal: PLoS One Date: 2014-03-06 Impact factor: 3.240
Authors: Olga V Saik; Pavel S Demenkov; Timofey V Ivanisenko; Elena Yu Bragina; Maxim B Freidin; Victor E Dosenko; Olga I Zolotareva; Evgeniy L Choynzonov; Ralf Hofestaedt; Vladimir A Ivanisenko Journal: J Integr Bioinform Date: 2018-12-25
Authors: Dirk M Wuttge; Marie Wildt; Pierre Geborek; Frank A Wollheim; Agneta Scheja; Anita Akesson Journal: Arthritis Res Ther Date: 2007 Impact factor: 5.156
Authors: Rajeev Malhotra; Samuel Paskin-Flerlage; Roham T Zamanian; Patrick Zimmerman; Jonathan W Schmidt; Donna Y Deng; Mark Southwood; Robert Spencer; Carol S Lai; William Parker; Richard N Channick; Nicholas W Morrell; C Gregory Elliott; Paul B Yu Journal: Pulm Circ Date: 2013-04 Impact factor: 3.017